基于树状数据挖掘评估新冠疫苗首次加强针安全性的疫苗安全数据链研究
本研究利用疫苗安全数据链(VSD)对2022年4月2日前接种新冠疫苗首次加强针者随访56天,采用自控树状时序扫描统计量进行非靶向数据挖掘。结果发现Moderna加强针后第10-15天出现荨麻疹/过敏/皮疹聚集(p=0.0001),mRNA加强针后还出现未特指不良反应、常见疫苗反应和新冠聚集,Janssen基础免疫后加强针未见值得关注的聚集。
要点
- Moderna加强针后第10-15天检测到荨麻疹/过敏/皮疹聚集(p=0.0001)。
- mRNA加强针后还出现未特指不良反应、发热和肌痛等常见反应及新冠聚集。
- 新冠聚集出现在加强针后第1-10天,早于加强针生效时间。
核心结论
- 在本次非靶向数据挖掘研究中,Moderna加强针后检测到迟发性荨麻疹/过敏/皮疹聚集,此前已有Moderna疫苗接种后类似报告。
- mRNA加强针后的其他聚集为未特指或常见不良反应以及新冠,后者显然反映接种10天后对新冠的免疫力。
- Janssen基础免疫后接种加强针未见值得关注的聚集。
研究设计与样本
- 研究利用美国疾病控制与预防中心的疫苗安全数据链(VSD),对2022年4月2日前接种新冠疫苗首次加强针的VSD参保者随访56天。
- 对住院或急诊就诊的新发诊断,在ICD-10-CM分层编码结构和随访期内分析聚集性,采用自控树状时序扫描统计量,以每个诊断的总病例数为条件。
- P值通过蒙特卡洛模拟估计,预设p=0.01为聚集统计学显著性的截断值。
- 评估的加强针包括辉瑞-BioNTech(BNT162b2)、Moderna(mRNA-1273)和Janssen(Ad26.COV2.S)新冠疫苗。
主要发现
- Moderna加强针后第10-15天发现荨麻疹/过敏/皮疹聚集(p=0.0001)。
- mRNA加强针后的其他聚集大多p=0.0001,包括未特指不良反应、发热和肌痛等常见疫苗相关反应以及新冠。
- 新冠聚集出现在加强针接种后第1-10天,早于加强针生效时间。
- Janssen基础免疫后接种加强针未见值得关注的聚集。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Centers for Disease Control and Prevention's Vaccine Safety Datalink (VSD) has been performing safety surveillance for COVID-19 vaccines since their earliest authorization in the United States. Complementing its real-time surveillance for pre-specified health outcomes using pre-specified risk intervals, the VSD conducts tree-based data-mining to look for clustering of a broad range of health outcomes after COVID-19 vaccination. This study's objective was to use this untargeted, hypothesis-generating approach to assess the safety of first booster doses of Pfizer-BioNTech (BNT162b2), Moderna (mRNA-1273), and Janssen (Ad26.COV2.S) COVID-19 vaccines. METHODS: VSD enrollees receiving a first booster of COVID-19 vaccine through April 2, 2022 were followed for 56 days. Incident diagnoses in inpatient or emergency department settings were analyzed for clustering within both the hierarchical ICD-10-CM code structure and the follow-up period. The self-controlled tree-temporal scan statistic was used, conditioning on the total number of cases for each diagnosis. P-values were estimated by Monte Carlo simulation; p = 0.01 was pre-specified as the cut-off for statistical significance of clusters. RESULTS: More than 2.4 and 1.8 million subjects received Pfizer-BioNTech and Moderna boosters after an mRNA primary series, respectively. Clusters of urticaria/allergy/rash were found during Days 10-15 after the Moderna booster (p = 0.0001). Other outcomes that clustered after mRNA boosters, mostly with p = 0.0001, included unspecified adverse effects, common vaccine-associated reactions like fever and myalgia, and COVID-19. COVID-19 clusters were in Days 1-10 after booster receipt, before boosters would have become effective. There were no noteworthy clusters after boosters following primary Janssen vaccination. CONCLUSIONS: In this untargeted data-mining study of COVID-19 booster vaccination, a cluster of delayed-onset urticaria/allergy/rash was detected after the Moderna booster, as has been reported after Moderna vaccination previously. Other clusters after mRNA boosters were of unspecified or common adverse effects and COVID-19, the latter evidently reflecting immunity to COVID-19 after 10 days.
引用
- Katherine Yih W, Daley MF, Duffy J, et al. Tree-based data mining for safety assessment of first COVID-19 booster doses in the Vaccine Safety Datalink. Vaccine. 2022. PMID: 36481108. doi:10.1016/j.vaccine.2022.11.053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。